Cargando…
Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models
BACKGROUND: Evaluation of parasite clearance patterns in experimental human infection trials helps increase understanding of drug action. In a previously reported phase Ib trial of a new investigational anti-malarial drug M5717, parasite clearance showed a biphasic linear pattern: slow removal phase...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303793/ https://www.ncbi.nlm.nih.gov/pubmed/37381013 http://dx.doi.org/10.1186/s12936-023-04627-x |
_version_ | 1785065359148056576 |
---|---|
author | Yin, Xiaoyan Li, Ying Bagchus, Wilhelmina Yalkinoglu, Özkan Bezuidenhout, Deon Tappert, Aliona McCarthy, James Marquart, Louise Oeuvray, Claude |
author_facet | Yin, Xiaoyan Li, Ying Bagchus, Wilhelmina Yalkinoglu, Özkan Bezuidenhout, Deon Tappert, Aliona McCarthy, James Marquart, Louise Oeuvray, Claude |
author_sort | Yin, Xiaoyan |
collection | PubMed |
description | BACKGROUND: Evaluation of parasite clearance patterns in experimental human infection trials helps increase understanding of drug action. In a previously reported phase Ib trial of a new investigational anti-malarial drug M5717, parasite clearance showed a biphasic linear pattern: slow removal phase with a near flat clearance rate followed by a fast clearance phase with a steep slope. In this study three statistical approaches were implemented and compared to estimate the parasite clearance rate for each phase and the time point corresponding to the change of clearance rates (changepoint between the two phases). METHODS: Data using three M5717 doses 150 mg (n = 6), 400 mg (n = 8), 800 mg (n = 8) were used to estimate biphasic clearance rates. Three models were investigated: firstly, segmented mixed models with estimated changepoint—models with/without random effects in various parameters were compared. Secondly, a segmented mixed model using grid search—this method is similar to the first except that changepoints were not estimated, instead they were selected based on model fit from given candidate values. Thirdly, a two-stage approach whereby a segmented regression model fit to each participant followed by a meta-analysis method. Hourly rate of parasite clearance (HRPC) interpreted as the percentage of parasites removed each hour was calculated. RESULTS: The three models generated similar results. Using segmented mixed models, the estimated changepoints after treatment in hours (95% CI) were: 150 mg: 33.9 (28.7, 39.1); 400 mg: 57.4 (52.5, 62.4); and 800 mg: 52.8 (47.4, 58.1). For all three treatment groups, there was nearly no clearance before the changepoints, but rapid clearance in the second phase (HRPC [95% CI]): 150 mg: 16.8% (14.3, 19.1%); 400 mg: 18.6% (16.0, 21.1%); and 800 mg: 11.7% (9.3, 14.1%). CONCLUSIONS: All three statistical approaches are effective tools to characterize the bi-phasic clearance of M5717 in the phase 1b experimental Plasmodium falciparum malaria human infection study. The statistical approaches produced similar results to estimate the two-phase clearance rates and the changepoint for each treatment dose of M5717. However, the segmented mixed model with random changepoints has several advantages: it is computationally efficient, provides precision for changepoint estimates and is robust concerning outlying datapoints or individuals. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-023-04627-x. |
format | Online Article Text |
id | pubmed-10303793 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103037932023-06-29 Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models Yin, Xiaoyan Li, Ying Bagchus, Wilhelmina Yalkinoglu, Özkan Bezuidenhout, Deon Tappert, Aliona McCarthy, James Marquart, Louise Oeuvray, Claude Malar J Research BACKGROUND: Evaluation of parasite clearance patterns in experimental human infection trials helps increase understanding of drug action. In a previously reported phase Ib trial of a new investigational anti-malarial drug M5717, parasite clearance showed a biphasic linear pattern: slow removal phase with a near flat clearance rate followed by a fast clearance phase with a steep slope. In this study three statistical approaches were implemented and compared to estimate the parasite clearance rate for each phase and the time point corresponding to the change of clearance rates (changepoint between the two phases). METHODS: Data using three M5717 doses 150 mg (n = 6), 400 mg (n = 8), 800 mg (n = 8) were used to estimate biphasic clearance rates. Three models were investigated: firstly, segmented mixed models with estimated changepoint—models with/without random effects in various parameters were compared. Secondly, a segmented mixed model using grid search—this method is similar to the first except that changepoints were not estimated, instead they were selected based on model fit from given candidate values. Thirdly, a two-stage approach whereby a segmented regression model fit to each participant followed by a meta-analysis method. Hourly rate of parasite clearance (HRPC) interpreted as the percentage of parasites removed each hour was calculated. RESULTS: The three models generated similar results. Using segmented mixed models, the estimated changepoints after treatment in hours (95% CI) were: 150 mg: 33.9 (28.7, 39.1); 400 mg: 57.4 (52.5, 62.4); and 800 mg: 52.8 (47.4, 58.1). For all three treatment groups, there was nearly no clearance before the changepoints, but rapid clearance in the second phase (HRPC [95% CI]): 150 mg: 16.8% (14.3, 19.1%); 400 mg: 18.6% (16.0, 21.1%); and 800 mg: 11.7% (9.3, 14.1%). CONCLUSIONS: All three statistical approaches are effective tools to characterize the bi-phasic clearance of M5717 in the phase 1b experimental Plasmodium falciparum malaria human infection study. The statistical approaches produced similar results to estimate the two-phase clearance rates and the changepoint for each treatment dose of M5717. However, the segmented mixed model with random changepoints has several advantages: it is computationally efficient, provides precision for changepoint estimates and is robust concerning outlying datapoints or individuals. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12936-023-04627-x. BioMed Central 2023-06-28 /pmc/articles/PMC10303793/ /pubmed/37381013 http://dx.doi.org/10.1186/s12936-023-04627-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Yin, Xiaoyan Li, Ying Bagchus, Wilhelmina Yalkinoglu, Özkan Bezuidenhout, Deon Tappert, Aliona McCarthy, James Marquart, Louise Oeuvray, Claude Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models |
title | Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models |
title_full | Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models |
title_fullStr | Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models |
title_full_unstemmed | Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models |
title_short | Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models |
title_sort | evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial m5717 using segmented mixed effect models |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303793/ https://www.ncbi.nlm.nih.gov/pubmed/37381013 http://dx.doi.org/10.1186/s12936-023-04627-x |
work_keys_str_mv | AT yinxiaoyan evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels AT liying evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels AT bagchuswilhelmina evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels AT yalkinogluozkan evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels AT bezuidenhoutdeon evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels AT tappertaliona evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels AT mccarthyjames evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels AT marquartlouise evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels AT oeuvrayclaude evaluationofamultiphasicparasiteclearanceprofileaftertreatmentofexperimentalhumaninfectionwiththeinvestigationalantimalarialm5717usingsegmentedmixedeffectmodels |